Discovery and Characterization of a Brain-Penetrant SHP2 Inhibitor
Achieving sufficient unbound brain exposure while maintaining potent target inhibition is a major challenge in small-molecule drug discovery. This poster presents IRBM's integrated medicinal chemistry, pharmacology, and drug metabolism and pharmacokinetics strategy for an SHP2 inhibitor program. Compounds progress through a cascade that links CNS-relevant physicochemical design, complementary in vitro blood-brain barrier models, and in vivo rodent pharmacokinetics, using unbound brain exposure rather than potency alone to guide prioritization. This resource-efficient approach supported the selection of I-1000233, a brain-penetrant allosteric SHP2 inhibitor that achieves CNS exposure and efficacy in an orthotopic glioblastoma model. Download the poster to explore the optimization cascade, exposure data, and in vivo results in detail.
iPeptides: An Extensible Python Toolkit for 3D Modeling, Enumeration and QSAR of Peptides
Peptides offer clear advantages as a therapeutic modality, but drug-like properties often require non-natural amino acids, whose computational handling remains a major challenge. This poster presents iPeptides, IRBM's in-house Python toolkit that operates directly on the molecular chemical graph, treating natural and non-natural residues with the same rigor. Its extensible design connects HELM sequence notation to atomistic 3D models and integrates combinatorial enumeration of imported monomer libraries, machine-learning-based prioritization, and downstream modeling, including cross-link and cycle-size optimization. The result is a unified framework for systematically exploring peptide chemical space across diverse design challenges. Download the poster to explore the workflow in detail.
Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers
Targeted therapies for RAS-driven cancers can deliver strong initial responses, but tumors often develop adaptive resistance. SHP2-mediated feedback reactivates the MAPK pathway, undermining treatment response and driving disease recurrence. I-0436650 emerged as a potent, selective, and orally bioavailable allosteric SHP2…
Business Development Director / Senior Director – US Territories & DACH Region
Position Summary IRBM is seeking experienced, highly motivated, and results-driven Business Development Directors to support growth across designated territories in the United States and the DACH region (Germany, Austria, and Switzerland). The successful candidates will be responsible for identifying and…
The Sound of Structural Biology
We pointed a microphone at our protein production and NMR labs and let the science speak for itself.
Principal Research Scientist
Job Description We are seeking a talented, highly motivated Crystallographer with a strong passion for structural biology and structure-based drug discovery. The successful candidate will join a rapidly expanding Protein Production and NMR team and contribute to a collaborative, multidisciplinary…
IRBM Expands Its Purification and Automation Suite to Accelerate Drug Discovery Across Small Molecules, Peptides, PROTACs, and RNA Binders
For drug discovery teams advancing complex peptides, small molecules and new modalities, IRBM's expanded Purification and Automation Suite delivers a faster, more reliable path from synthesis to high-quality data required to drive confident decisions at every stage of the program…
C3PO: Complex 3D Patient Organoids for Preclinical Drug Testing in Brain Tumors
Reliable preclinical models represent one of the biggest limits in brain tumor drug discovery: classical 2D cell cultures rarely reproduce the cellular architecture and spatial organization of glioblastoma, so encouraging readouts often fail to translate. This poster outlines Complex 3D Patient Organoids (C3POs), engineered ex vivo spheroids that assemble patient-derived glioma stem-like cells with astrocytes and microglia in defined proportions, each population followed by fluorescent labeling and high-content imaging across a panel of molecular subtypes. Rebuilding this cellular context reshapes measured drug sensitivity and brings potency closer to tumor in vivo behavior, strengthening lead optimization, combination work, and subtype-specific testing. Download the poster to explore the model design and comparative drug-response data. A variant of this poster was presented at AACR 2026 and can be found further down this page.
